formoterol/glycopyrrolate (Bevespi Aerosphere)

Indications

• treatment of COPD

Dosage

• twice daily metered dose inhaler

formoterol fumarate (4.8 ug). glycopyrrolate (9 ug).

Adverse effects

• urinary tract infection (2.6% vs 2.3% with placebo)
• cough (4.0% vs 2.7% with placebo)

Mechanism of action

• long-acting muscarinic antagonist/long-acting beta-2 agonist combination

Notes

• FDA-approved April 27, 2016
• marketed by Atra-Zeneca

More general terms

• LABA/LAMA combination

Components

• formoterol (Foradil, Perforomist)
• glycopyrrolate (Robinul, Cuvposa, Qbrexza)